Manages vasospastic angina confirmed. ANDA 202644, held by Heritage Pharma. Nifedipine.
As of Nov 16, 2026, ANDA 202644 (Nifedipine), held by Heritage Pharma, was first approved by FDA on Apr 25, 2013, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE I. Vasospastic Angina Nifedipine is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 25, 2013 | Original application | Approved | None posted |
| Nifedipine10MG · capsule;oral | Nifedipine | Rx |
| Nifedipine20MG · capsule;oral | Nifedipine | Rx |
| Jan 26, 2016 | Supplement 4Labeling · Standard review | Approved | None posted |
| Dec 11, 2014 | Supplement 1Labeling · Standard review | Approved | None posted |
| Dec 11, 2014 | Supplement 2Labeling · Standard review | Approved | None posted |
| Apr 25, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters